IMS Capital Management Has $2.85 Million Holdings in Danaher Co. (NYSE:DHR)

IMS Capital Management decreased its stake in shares of Danaher Co. (NYSE:DHR) by 1.0% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 10,498 shares of the conglomerate’s stock after selling 108 shares during the quarter. Danaher comprises approximately 1.3% of IMS Capital Management’s investment portfolio, making the stock its 17th largest holding. IMS Capital Management’s holdings in Danaher were worth $2,852,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Tsfg LLC raised its stake in Danaher by 733.3% during the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after buying an additional 88 shares during the period. nVerses Capital LLC bought a new stake in shares of Danaher during the second quarter valued at approximately $25,000. CarsonAllaria Wealth Management Ltd. acquired a new position in shares of Danaher during the second quarter worth approximately $25,000. Redmont Wealth Advisors LLC bought a new position in shares of Danaher in the 1st quarter worth $30,000. Finally, Richardson Financial Services Inc. acquired a new stake in Danaher in the 4th quarter valued at $42,000. Institutional investors own 79.05% of the company’s stock.

Insider Activity

In related news, CFO Matthew Mcgrew sold 16,172 shares of the stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the sale, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at $8,229,254.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Matthew Mcgrew sold 16,172 shares of Danaher stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total value of $4,525,572.48. Following the transaction, the chief financial officer now owns 29,407 shares in the company, valued at approximately $8,229,254.88. The disclosure for this sale can be found here. Insiders have sold 39,659 shares of company stock valued at $11,042,433 in the last ninety days. Insiders own 11.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Royal Bank of Canada restated an “outperform” rating and set a $300.00 price objective on shares of Danaher in a report on Friday, September 6th. Stifel Nicolaus increased their price objective on Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a research note on Wednesday, July 24th. Jefferies Financial Group started coverage on Danaher in a research report on Monday, June 3rd. They set a “buy” rating and a $295.00 target price on the stock. Leerink Partners increased their price target on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. Finally, Robert W. Baird increased their price objective on shares of Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Seven equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and a consensus target price of $278.94.

Danaher Price Performance

DHR opened at $278.02 on Tuesday. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $281.70. The business has a fifty day moving average of $270.77 and a 200 day moving average of $258.06. The stock has a market cap of $205.93 billion, a P/E ratio of 47.12, a PEG ratio of 4.55 and a beta of 0.83. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating the consensus estimate of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the previous year, the business posted $2.05 EPS. The company’s quarterly revenue was down 2.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that Danaher Co. will post 7.59 EPS for the current year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.39%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s dividend payout ratio (DPR) is 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.